Altered ferritin subunit composition: change in iron metabolism in lens epithelial cells and downstream effects on glutathione levels and VEGF secretion.
OBJECTIVE
The iron storage protein ferritin is necessary for the safe storage of iron and for protection against the production of iron-catalyzed oxidative damage. Ferritin is composed of 24 subunits of two types: heavy (H) and light (L). The ratio of these subunits is tissue specific, and alteration of this ratio can have profound effects on iron storage and availability. In the present study, siRNA for each of the chains was used to alter the ferritin H:L chain ratio and to determine the effect of these changes on ferritin synthesis, iron metabolism, and downstream effects on iron-responsive pathways in canine lens epithelial cells.


METHODS
Primary cultures of canine lens epithelial cells were used. The cells were transfected with custom-made siRNA for canine ferritin H- and L-chains. De novo ferritin synthesis was determined by labeling newly synthesized ferritin chains with 35S-methionine, immunoprecipitation, and separation by SDS-PAGE. Iron uptake into cells and incorporation into ferritin was measured by incubating the cells with 59Fe-labeled transferrin. Western blot analysis was used to determine the presence of transferrin receptor, and ELISA was used to determine total ferritin concentration. Ferritin localization in the cells was determined by immunofluorescence labeling. VEGF, glutathione secretion levels, and cystine uptake were measured.


RESULTS
FHsiRNA decreased ferritin H-chain synthesis, but doubled ferritin L-chain synthesis. FLsiRNA decreased both ferritin H- and L-chain synthesis. The degradation of ferritin H-chain was blocked by both siRNAs, whereas only FHsiRNA blocked the degradation of ferritin L-chain, which caused significant accumulation of ferritin L-chain in the cells. This excess ferritin L-chain was found in inclusion bodies, some of which were co-localized with lysosomes. Iron storage in ferritin was greatly reduced by FHsiRNA, resulting in increased iron availability, as noted by a decrease in transferrin receptor levels and iron uptake from transferrin. Increased iron availability also increased cystine uptake and glutathione concentration and decreased nuclear translocation of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor (VEGF) accumulation in the cell-conditioned medium.


CONCLUSIONS
Most of the effects of altering the ferritin H:L ratio with the specific siRNAs were due to changes in the availability of iron in a labile pool. They caused significant changes in iron uptake and storage, the rate of ferritin synthesis and degradation, the secretion of VEGF, and the levels of glutathione in cultured lens epithelial cells. These profound effects clearly demonstrate that maintenance of a specific H:L ratio is part of a basic cellular homeostatic mechanism.
Harned
Jill
J
Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina 27606, USA.
Ferrell
Jenny
J
Lall
Marilyn M
MM
Fleisher
Lloyd N
LN
Nagar
Steven
S
Goralska
Malgorzata
M
McGahan
M Christine
MC
D000818:Animals; D001052:Apoferritins / Q000235:genetics / Q000378:metabolism*; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D003553:Cystine / Q000493:pharmacokinetics; D004285:Dogs; D004847:Epithelial Cells / Q000166:cytology / Q000378:metabolism*; D005978:Glutathione / Q000378:metabolism*; D006706:Homeostasis / Q000502:physiology; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D007501:Iron / Q000378:metabolism*; D007908:Lens, Crystalline / Q000166:cytology / Q000378:metabolism*; D018384:Oxidative Stress / Q000502:physiology; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D017077:Culture Media, Conditioned; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D021122:Protein Subunits; D034741:RNA, Small Interfering; D042461:Vascular Endothelial Growth Factor A; D003553:Cystine; D001052:Apoferritins; D007501:Iron; D005978:Glutathione
Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3968-75
17724174
J Biol Chem. 2003 Oct 31;278(44):42920-6
12920121
J Biol Chem. 2007 Aug 3;282(31):22335-43
17565989
Cell. 2004 Apr 30;117(3):285-97
15109490
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1721-7
11431434
Cell. 2001 Oct 5;107(1):43-54
11595184
Cancer Res. 2002 Dec 1;62(23):6924-7
12460908
Invest Ophthalmol Vis Sci. 2008 Jan;49(1):310-9
18172108
Blood. 1998 Jun 1;91(11):4180-7
9596665
Blood. 1999 Nov 15;94(10):3593-603
10552971
J Biol Chem. 2000 Aug 18;275(33):25122-9
10833524
FEBS Lett. 2003 Feb 27;537(1-3):187-92
12606055
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3911-9
12939309
Circ Res. 1995 Sep;77(3):638-43
7641334
Mol Cell Biol. 1996 Sep;16(9):4604-13
8756616
J Biol Chem. 2001 Dec 28;276(52):48775-80
11606570
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3521-9
16186329
Am J Physiol Cell Physiol. 2005 May;288(5):C1117-24
15613494
Blood. 1996 Mar 1;87(5):2057-64
8634457
Blood. 2004 Mar 15;103(6):2377-83
14615379
Antioxid Redox Signal. 2008 Jun;10(6):997-1030
18327971
Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1895-902
19151392
Ann N Y Acad Sci. 2004 Mar;1012:1-13
15105251
Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203
8695634
Carcinogenesis. 2007 Sep;28(9):2047-52
17434931
J Biol Chem. 1993 Jun 15;268(17):12744-8
8509409
J Med Genet. 2004 Jun;41(6):e81
15173247
Science. 2001 Nov 9;294(5545):1337-40
11598268
Exp Eye Res. 1998 Jun;66(6):687-97
9657901
Blood. 1995 Dec 1;86(11):4050-3
7492760